ZYDUS WELLNESS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,747 INR | -0.26% |
|
+1.96% | +4.12% |
| 05-14 | Transcript : Zydus Wellness Limited, Q4 2024 Earnings Call, May 14, 2024 | |
| 05-14 | Zydus Wellness Sees Rise in Fiscal Q4 Consolidated Net Profit | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 74,874 | 74,790 | 125,533 | 95,496 | 98,623 | 111,445 | - | - |
| Enterprise Value (EV) 1 | 89,155 | 89,436 | 129,294 | 97,343 | 100,467 | 93,597 | 108,460 | 107,093 |
| P/E ratio | 32.4 x | 52.8 x | 101 x | 30.9 x | 31.8 x | 35.1 x | 28.3 x | 27.5 x |
| Yield | - | - | 0.25% | 0.33% | 0.32% | 0.42% | 0.31% | 0.24% |
| Capitalization / Revenue | 8.88 x | 4.23 x | 6.72 x | 4.75 x | 4.37 x | 4.02 x | 4.3 x | 3.85 x |
| EV / Revenue | 10.6 x | 5.06 x | 6.93 x | 4.85 x | 4.46 x | 4.02 x | 4.18 x | 3.7 x |
| EV / EBITDA | 51.1 x | 32.3 x | 60.9 x | 28.2 x | 29.8 x | 30.4 x | 26 x | 21.3 x |
| EV / FCF | 67.4 x | 38.1 x | 48.5 x | 60.3 x | 212 x | 31.5 x | 30.7 x | 33.1 x |
| FCF Yield | 1.48% | 2.62% | 2.06% | 1.66% | 0.47% | 3.18% | 3.26% | 3.02% |
| Price to Book | 2.21 x | 2.16 x | 2.62 x | 1.97 x | 1.93 x | 2.1 x | 1.98 x | 1.9 x |
| Nbr of stocks (in thousands) | 57,664 | 57,664 | 63,632 | 63,632 | 63,632 | 63,632 | - | - |
| Reference price 2 | 1,298 | 1,297 | 1,973 | 1,501 | 1,550 | 1,751 | 1,751 | 1,751 |
| Announcement Date | 5/28/19 | 6/2/20 | 5/10/21 | 5/17/22 | 5/17/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,428 | 17,668 | 18,667 | 20,091 | 22,548 | 23,278 | 25,917 | 28,957 |
| EBITDA 1 | 1,744 | 2,769 | 2,122 | 3,448 | 3,372 | 3,082 | 4,176 | 5,031 |
| EBIT 1 | 1,618 | 2,505 | 1,871 | 3,211 | 3,121 | 2,844 | 3,908 | 4,717 |
| Operating Margin | 19.2% | 14.18% | 10.02% | 15.98% | 13.84% | 12.22% | 15.08% | 16.29% |
| Earnings before Tax (EBT) 1 | 1,706 | 1,213 | 1,122 | 3,060 | 2,909 | 2,601 | 3,942 | 4,955 |
| Net income 1 | 1,691 | 1,417 | 1,187 | 3,089 | 3,104 | 2,669 | 3,942 | 4,057 |
| Net margin | 20.07% | 8.02% | 6.36% | 15.37% | 13.76% | 11.47% | 15.21% | 14.01% |
| EPS 2 | 40.10 | 24.58 | 19.55 | 48.54 | 48.78 | 41.94 | 61.80 | 63.77 |
| Free Cash Flow 1 | 1,323 | 2,346 | 2,668 | 1,614 | 473.8 | 3,522 | 3,531 | 3,232 |
| FCF margin | 15.7% | 13.28% | 14.3% | 8.03% | 2.1% | 15.19% | 13.62% | 11.16% |
| FCF Conversion (EBITDA) | 75.89% | 84.74% | 125.74% | 46.82% | 14.05% | 110.27% | 84.55% | 64.23% |
| FCF Conversion (Net income) | 78.23% | 165.55% | 224.75% | 52.26% | 15.27% | 121.23% | 89.57% | 79.65% |
| Dividend per Share 2 | - | - | 5.000 | 5.000 | 5.000 | 7.333 | 5.500 | 4.167 |
| Announcement Date | 5/28/19 | 6/2/20 | 5/10/21 | 5/17/22 | 5/17/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,816 | 6,057 | 5,976 | 3,836 | 3,881 | 6,398 | 6,968 | 4,295 | 4,156 | 7,130 | 7,021 | 4,557 | 4,282 | 5,203 |
| EBITDA 1 | 495.3 | 1,454 | 1,404 | 305.4 | 322.9 | 1,415 | 1,481 | 162.6 | 281.9 | 1,446 | 1,165 | 294.5 | 276 | 1,331 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | 1,308 | - | 227.2 | 1,314 | 1,370 | - | 193.1 | - | 934 | - | - | - |
| Net income 1 | - | - | 1,308 | - | 233 | 1,333 | 1,370 | 84.7 | 195.6 | 1,453 | 1,104 | - | - | - |
| Net margin | - | - | 21.89% | - | 6% | 20.84% | 19.66% | 1.97% | 4.71% | 20.38% | 15.72% | - | - | - |
| EPS 2 | - | - | - | - | 3.660 | 20.95 | 21.53 | - | - | - | 17.35 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/1/21 | 5/10/21 | 7/30/21 | 10/28/21 | 2/2/22 | 5/17/22 | 7/29/22 | 11/10/22 | 2/2/23 | 5/17/23 | 8/3/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 14,281 | 14,646 | 3,760 | 1,847 | 1,844 | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 566 | 2,985 | 4,352 |
| Leverage (Debt/EBITDA) | 8.191 x | 5.29 x | 1.772 x | 0.5357 x | 0.5468 x | - | - | - |
| Free Cash Flow 1 | 1,323 | 2,346 | 2,669 | 1,614 | 474 | 3,522 | 3,531 | 3,232 |
| ROE (net income / shareholders' equity) | 8.27% | 4.2% | 6.25% | 6.56% | 6.43% | 5.2% | 7.08% | 7.14% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 587.0 | 600.0 | 752.0 | 761.0 | 805.0 | 833.0 | 882.0 | 920.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 171 | 246 | 197 | 754 | 443 | 330 | 270 | 465 |
| Capex / Sales | 2.03% | 1.39% | 1.05% | 3.75% | 1.97% | 1.42% | 1.04% | 1.61% |
| Announcement Date | 5/28/19 | 6/2/20 | 5/10/21 | 5/17/22 | 5/17/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1,751
INR
Average target price
1,883
INR
Spread / Average Target
+7.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.12% | 1.34B | |
| -2.02% | 277B | |
| -1.52% | 95.68B | |
| -3.06% | 43.53B | |
| +10.17% | 41.54B | |
| +1.60% | 41.59B | |
| +7.20% | 39.42B | |
| -16.81% | 29.71B | |
| -7.27% | 28.5B | |
| +14.53% | 25.64B |
- Stock Market
- Equities
- ZYDUSWELL Stock
- Financials Zydus Wellness Limited
